Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma
- 26 June 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 27 (1), 252-255
- https://doi.org/10.1038/leu.2012.172
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphomaSupportive Care in Cancer, 2011
- Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I studyLeukemia, 2011
- Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopeniaAnnals Of Oncology, 2011
- Long-Term Follow-Up of Patients With Newly Diagnosed Follicular Lymphoma in the Prerituximab Era: Effect of Response Quality on Survival—A Study From the Groupe d'Etude des Lymphomes de l'AdulteJournal of Clinical Oncology, 2010
- Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapyBlood, 2009
- Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's LymphomaJournal of Clinical Oncology, 2009
- Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivoAmerican Journal of Hematology, 2009
- Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor CellsClinical Cancer Research, 2008
- Lenalidomide for the Treatment of B-Cell MalignanciesJournal of Clinical Oncology, 2008
- Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupBlood, 2005